Risk Factors Update Summary

• The dissolution of Inexia Limited, Janpix Limited, Ultrahuman Two Limited, and Ultrahuman Four Limited is planned.
• The company may not be able to terminate certain growth strategies, leading to potential delays.
• Despite benefits of corporate restructuring, residual risk associated with one or more subsidiaries remains.
• The negotiation process is time-consuming, costly, and complex. This may expose us to a material adverse effect on operations.
• The company may face difficulties in retaining employees and consultants, impacting expansion plans.
• Lawsuit transferred to New York, amended complaint filed, focusing on IPO misstatements.
• In mid-2023, a corporate consolidation transferred business operations and assets to Centessa Pharmaceuticals (UK) Limited.
• The company implemented a corporate consolidation to simplify administrative operations and improve control environment.
• ERP system implementation to enhance operations, upgrade processes, and improve financial reporting.
• The company intends to dissolve Z Factor Limited, Centessa Pharmaceuticals (Morphogen-IX) Limited, Capella Bioscience Ltd, LockBody Therapeutics Ltd, and Centessa Pharmaceuticals (Orexia) Limited.
• Holders of 50,034 ADSs may sell, with 60.5% voting shares held by shareholders.
• ERP system implementation costly, requiring significant resources, potentially affecting operations and financial condition.
• Uncertainty regarding PFIC status for the company and its subsidiaries for past, current, and future tax years.
• Global economic conditions could adversely affect business operations, financial condition, and results.